JAZZ

Jazz PublicB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$300.00

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$255.00

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$210.00

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-13

AI commentary

News buzz is high because of the Q2 earnings release, raised guidance, the August 25 FDA decision, and the Actio acquisition. Net tone is mixed-to-positive: operating results and guidance improved, while LAGOON remains an overhang. No usable social, post-print price-reaction, consensus-surprise, or analyst-revision data was provided, so confidence remains moderate rather than bullish.

RankAlpha Sentiment Codex - 2026-08-13

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-08-25eventZiihera first-line GEA FDA decisionHigh impact

The company reiterated an August 25, 2026 PDUFA date for zanidatamab combinations in first-line HER2-positive gastroesophageal adenocarcinoma; approval would support a new oncology growth leg, while a delay or rejection would pressure sentiment [#SEC-8K-2026-08-03].

2026-11-11eventHERIZON-GEA-01 second interim overall-survival dataMedium impact

Top-line results from the second interim overall-survival analysis for the zanidatamab doublet regimen are expected in the third quarter of 2026, creating a meaningful clinical and commercial readout risk/reward [#SEC-8K-2026-08-03].

2026-11-11eventActio Biosciences acquisition executionMedium impact

Jazz entered a merger agreement to acquire Actio for an initial aggregate upfront value of $820 million, plus up to $500 million of contingent milestones tied to ABS-1230 development and sales. The transaction adds pipeline optionality but raises execution and capital-allocation risk [#8-K-2026-08-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-13 • Updated nightlySource: Internal modelMethodology